SEARCH

SEARCH BY CITATION

Literature Cited

  • 1
    Clarke MF,Dick JE,Dirks PB,Eaves CJ,Jamieson CH,Jones DL,Visvader J,Weissman IL,Wahl GM. Cancer stem cells—perspectives on current status and future directions: AACR workshop on cancer stem cells. Cancer Res 2006; 66: 93399344.
  • 2
    Gangemi R,Paleari L,Orengo AM,Cesario A,Chessa L,Ferrini S,Russo P. Cancer stem cells: A new paradigm for understanding tumor progression and therapeutic resistance. Curr Med Chem 2009; 16: 16881703.
  • 3
    Heaney ML,Golde DW. Myelodysplasia. N Engl J Med 1999; 340: 16491660.
  • 4
    Corey SJ,Minden MD,Barber DL,Kantarjian H,Wang JC,Schimmer AD. Myelodysplastic syndromes: The complexity of stem-cell diseases. Nat Rev Cancer 2007; 7: 118129.
  • 5
    Nimer SD. MDS: A stem cell disorder-but what exactly is wrong with the primitive hematopoietic cells in this disease? Hematology Am Soc Hematol Educ Program 2008: 4351.
  • 6
    Bonnett D,Dick JE. Human acute myeloid leukaemia is organized as a hierarchy that originates from a primate haematopoietic cell. Nat Med 1997; 3: 730737.
  • 7
    Hosen N,Park CY,Tatsumi N,Oji Y,Sugiyama H,Gramatzki M,Krensky AM,Weissman IL. CD96 is a leukemic stem cell-specific marker in human acute myeloid leukemia. Proc Natl Acad Sci USA 2007; 104: 1100811013.
  • 8
    Jordan CT,Upchurch D,Szilvassy SJ,Guzman ML,Howard DS,Pettigrew AL,Meyerrose T,Rossi R,Grimes B,Rizzieri DA,Luger SM,Phillips GL. The interleukin-3 receptor alpha chain is a unique marker for human acute myelogenous leukemia stem cells. Leukemia 2000; 14: 17771784.
  • 9
    Blair A,Hogge DE,Ailles LE,Lansdorp PM,Sutherland HJ. Lack of expression of Thy-1 (CD90) on acute myeloid leukemia cells with long term proliferation ability in vitro and in vivo. Blood 1997; 89: 31043112.
  • 10
    Florian S,Sonneck K,Hauswirth AW,Krauth MT,Schernthaner GH,Sperr WR,Valent P. Detection of molecular targets on the surface of CD34+/CD38-stem cells in various myeloid malignancies. Leuk Lymphoma 2006; 47: 207222.
  • 11
    Hauswirth AW,Florian S,Printz D,Sotlar K,Krauth MT,Fritsch G,Schernthaner GH,Wacheck V,Selzer E,Sperr WR,Valent P. Expression of the target receptor CD33 in CD34+/CD38-/CD123+ AML stem cells. Eur J Clin Invest 2007; 37: 7382.
  • 12
    Jin L,Hope KJ,Zhai Q,Smadja-Joffe F,Dick JE. Targeting of CD44 eradicates human acute myeloid leukemic stem cells. Nat Med 2006; 12: 11671174.
  • 13
    Misaghian N,Ligresti G,Steelman LS,Bertrand FE,Bäsecke J,Libra M,Nicoletti F,Stivala F,Milella M,Tafuri A,Cervello M,Martelli AM,McCubrey JA. Targeting the leukemic stem cell: The Holy Grail of leukemia therapy. Leukemia 2009; 23: 2542.
  • 14
    Van Rhenen A,van Dongen GA,Kelder A,Rombouts EJ,Feller N,Moshaver B,Stigter-van Walsum M,Zweegman S,Ossenkoppele GJ,Jan Schuurhuis G. The novel AML stem cell-associated antigen CLL-1 aids in discrimination between normal and leukemic stem cells. Blood 2007; 110: 26592666.
  • 15
    Taussig DC,Pearce DJ,Simpson C,Rohatiner AZ,Lister TA,Kelly G,Luongo JL,Danet-Desnoyers GA,Bonnet D. Hematopoietic stem cells express multiple myeloid markers: Implications for the origin and targeted therapy of acute myeloid leukemia. Blood 2005; 106: 40864092.
  • 16
    Van Gosliga D,Schepers H,Rizo A,van der Kolk D,Vellenga E,Schuringa JJ. Establishing long-term cultures with self-renewing acute myeloid leukemia stem/progenitor cells. Exp Hematol 2007; 35: 15381549.
  • 17
    Nilsson L,Astrand-Grundström I,Anderson K,Arvidsson I,Hokland P,Bryder D,Kjeldsen L,Johansson B,Hellström-Lindberg E,Hast R,Jacobsen SE. Involvement and functional impairment of the CD34(+)CD38(−)Thy-1(+) hematopoietic stem cell pool in myelodysplastic syndromes with trisomy 8. Blood 2002; 100: 259267.
  • 18
    Kussick SJ,Fromm JR,Rossini A,Li Y,Chang A,Norwood TH,Wood BL. Four-color flow cytometry shows strong concordance with bone marrow morphology and cytogenetics in the evaluation for myelodysplasia. Am J Clin Pathol 2005; 124: 170181.
  • 19
    Matarraz S,López A,Barrena S,Fernandez C,Jensen E,Flores J,Bárcena P,Rasillo A,Sayagues JM,Sánchez ML,Hernandez-Campo P,Hernandez Rivas JM,Salvador C,Fernandez-Mosteirín N,Giralt M,Perdiguer L,Orfao A. The immunophenotype of different immature, myeloid and B-cell lineage-committed CD34+ hematopoietic cells allows discrimination between normal/reactive and myelodysplastic syndrome precursors. Leukemia 2008; 22: 11751183.
  • 20
    Bakker AB,van den Oudenrijn S,Bakker AQ,Feller N,van Meijer M,Bia JA,Jongeneelen MA,Visser TJ,Bijl N,Geuijen CA,Marissen WE,Radosevic K,Throsby M,Schuurhuis GJ,Ossenkoppele GJ,de Kruif J,Goudsmit J,Kruisbeek AM. C-type lectin-like molecule-1: A novel myeloid cell surface marker associated with acute myeloid leukemia. Cancer Res 2004; 64: 84438450.
  • 21
    Vardiman JW,Harris NL,Brunning RD. The World Health Organization (WHO) classification of the myeloid neoplasms. Blood 2002; 100: 22922302.
  • 22
    Greenberg P,Cox C,LeBeau MM,Fenaux P,Morel P,Sanz G,Sanz M,Vallespi T,Hamblin T,Oscier D,Ohyashiki K,Toyama K,Aul C,Mufti G,Bennett J. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood 1997; 89: 20792088.
  • 23
    Reya T,Morrison SJ,Clarke MF,Weissman IL. Stem cells, cancer and cancer stem cells. Nature 2001; 414: 105111.
  • 24
    Spillane JB,Henderson MA. Cancer stem cells: a review. ANZ J Surg 2007; 77: 464468.
  • 25
    Villamor N,Zarco M-A,Rozman M,Ribera J-M,Feliu E,Montserrat E. Acute myeloblastic leukemia with minimal myeloid differentiation: Phenotypical and ultrastructural characteristics. Leukemia 1998; 12: 10711075.
  • 26
    Costello R,Mallet F,Chambost H,Sainty D,Arnoulet C,Gastaut JA,Olive D. The immunophenotype of minimally differentiated acute myeloid leukemia (AML-M0): Reduced immunogenicity and high frequency of CD34+/CD38- leukemic progenitors. Leukemia 1999; 13: 15131518.
  • 27
    Della Porta MG,Malcovati L,Boveri E,Travaglino E,Pietra D,Pascutto C,Passamonti F,Invernizzi R,Castello A,Magrini U,Lazzarino M,Cazzola M. Clinical relevance of bone marrow fibrosis and CD34-positive cell clusters in primary myelodysplastic syndromes. J Clin Oncol 2009; 27: 754762.
  • 28
    Cazzola M. Flow cytometry immunophenotyping for diagnosis of myelodysplastic syndrome. Haematologica 2009; 94: 10411043.
  • 29
    Vercauteren SM,Sutherland HJ. CD133 (AC133) expression on AML cells and progenitors. Cytotherapy 2001; 3: 449459.
  • 30
    Pirruccello SJ,Young KH,Aoun P. Myeloblast phenotypic changes in myelodysplasia. CD34 and CD117 expression abnormalities are common. Am J Clin Pathol 2006; 125: 884894.
  • 31
    Ogata K,Kishikawa Y,Satoh C,Tamura H,Dan K,Hayashi A. Diagnostic application of flow cytometric characteristics of CD34+ cells in low-grade myelodysplastic syndromes. Blood 2006; 108: 10371044.
  • 32
    Ogata K,Nakamura K,Yokose N,Tamura H,Tachibana M,Taniguchi O,Iwakiri R,Hayashi T,Sakamaki H,Murai Y,Tohyama K,Tomoyasu S,Nonaka Y,Mori M,Dan K,Yoshida Y. Clinical significance of phenotypic features of blasts in patients with myelodysplastic syndrome. Blood 2002; 100: 38873896.
  • 33
    Yin AH,Miraglia S,Zanjani ED,Almeida-Porada G,Ogawa M,Leary AG,Olweus J,Kearney J,Buck DW. AC133, a novel marker for human hematopoietic stem and progenitor cells. Blood 1997; 90: 50025012.
  • 34
    Auberger J,Dlaska M,Auberger T,Gunsilius E,Wöll E,Hilbe W. Increased CD133 expression in bone marrow of myelodysplastic syndromes. Leuk Res 2005; 29: 9951001.
  • 35
    van de Loosdrecht AA,Westers TM,Westra AH,Drager AM,van der Velden VHJ,Ossenkoppele GJ. Identification of distinct prognostic subgroups in low- and intermediate-1-risk myelodysplastic syndromes by flow cytometry. Blood 2008; 111: 10671077.
  • 36
    Sridhar K,Ross DT,Tibshirani R,Butte AJ,Greenberg PL. Relationship of differential gene expression profiles in CD34+ myelodysplastic syndrome marrow cells to disease subtype and progression. Blood 2009; 114: 48474858.
  • 37
    Taussig DC,Vargaftig J,Miraki-Moud F,Griessinger E,Sharrock K,Luke T,Lillington D,Oakervee H,Cavenagh J,Agrawal SG,Lister TA,Gribben JG,Bonnet D. Leukemia-initiating cells from some acute myeloid leukemia patients with mutated nucleophosmin reside in the CD34(−) fraction. Blood 2010; 115: 19761984.